NASDAQ:ARWR

Arrowhead Pharmaceuticals Stock Forecast, Price & News

$68.37
+0.45 (+0.66 %)
(As of 07/23/2021 12:00 AM ET)
Add
Compare
Today's Range
$66.56
$68.63
50-Day Range
$62.54
$90.32
52-Week Range
$32.86
$93.66
Volume408,413 shs
Average Volume1.19 million shs
Market Capitalization$7.12 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.26
30 days | 90 days | 365 days | Advanced Chart
Receive ARWR News and Ratings via Email

Sign-up to receive the latest news and ratings for Arrowhead Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Arrowhead Pharmaceuticals logo

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc. operates as a biopharmaceutical company. It develops medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.64 out of 5 stars

Medical Sector

407th out of 2,215 stocks

Pharmaceutical Preparations Industry

192nd out of 867 stocks

Analyst Opinion: 3.4Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Arrowhead Pharmaceuticals (NASDAQ:ARWR) Frequently Asked Questions

Is Arrowhead Pharmaceuticals a buy right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arrowhead Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Arrowhead Pharmaceuticals stock.
View analyst ratings for Arrowhead Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Arrowhead Pharmaceuticals?

Wall Street analysts have given Arrowhead Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Arrowhead Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Arrowhead Pharmaceuticals' next earnings date?

Arrowhead Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Arrowhead Pharmaceuticals
.

How can I listen to Arrowhead Pharmaceuticals' earnings call?

Arrowhead Pharmaceuticals will be holding an earnings conference call on Thursday, August 5th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 404-537-3406 with passcode "7398304".

How were Arrowhead Pharmaceuticals' earnings last quarter?

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) released its earnings results on Monday, May, 3rd. The biotechnology company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.09) by $0.17. The biotechnology company had revenue of $32.81 million for the quarter, compared to analyst estimates of $39.42 million. Arrowhead Pharmaceuticals had a negative trailing twelve-month return on equity of 23.64% and a negative net margin of 122.97%. Arrowhead Pharmaceuticals's revenue for the quarter was up 39.4% on a year-over-year basis.
View Arrowhead Pharmaceuticals' earnings history
.

How has Arrowhead Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Arrowhead Pharmaceuticals' stock was trading at $28.56 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ARWR shares have increased by 139.4% and is now trading at $68.37.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for ARWR?

10 brokerages have issued 12-month price targets for Arrowhead Pharmaceuticals' stock. Their forecasts range from $34.00 to $110.00. On average, they expect Arrowhead Pharmaceuticals' stock price to reach $86.45 in the next twelve months. This suggests a possible upside of 26.5% from the stock's current price.
View analysts' price targets for Arrowhead Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Arrowhead Pharmaceuticals' key executives?

Arrowhead Pharmaceuticals' management team includes the following people:
  • Christopher Richard Anzalone, President, Chief Executive Officer & Director
  • Kenneth Allen Myszkowski, Chief Financial Officer
  • Javier San Martin, Chief Medical Officer
  • Jeff Ketelhut, Vice President-Information Technology & Systems
  • Patrick C. O'brien, Secretary & Chief Compliance Office

Who are some of Arrowhead Pharmaceuticals' key competitors?

What other stocks do shareholders of Arrowhead Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arrowhead Pharmaceuticals investors own include Bellicum Pharmaceuticals (BLCM), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Alliance Resource Partners (ARLP), Bank of America (BAC), Tesla (TSLA), salesforce.com (CRM) and Advanced Micro Devices (AMD).

What is Arrowhead Pharmaceuticals' stock symbol?

Arrowhead Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARWR."

Who are Arrowhead Pharmaceuticals' major shareholders?

Arrowhead Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Oregon Public Employees Retirement Fund (0.03%), New Mexico Educational Retirement Board (0.02%), Stratos Wealth Partners LTD. (0.01%), Fulton Bank N.A. (0.00%) and Sound Income Strategies LLC (0.00%). Company insiders that own Arrowhead Pharmaceuticals stock include Backer Marianne De, Bruce D Given, Christopher Richard Anzalone, Douglas B Given, Douglas B Given, James C Hamilton, James Hassard, James Hassard, Kenneth Allen Myszkowski, Martin Javier San, Mauro Ferrari, Michael S Perry, Patrick O'brien and William D Waddill.
View institutional ownership trends for Arrowhead Pharmaceuticals
.

Which major investors are buying Arrowhead Pharmaceuticals stock?

ARWR stock was bought by a variety of institutional investors in the last quarter, including New Mexico Educational Retirement Board, Oregon Public Employees Retirement Fund, Stratos Wealth Partners LTD., Sound Income Strategies LLC, and Fulton Bank N.A..
View insider buying and selling activity for Arrowhead Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Arrowhead Pharmaceuticals?

Shares of ARWR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arrowhead Pharmaceuticals' stock price today?

One share of ARWR stock can currently be purchased for approximately $68.37.

How much money does Arrowhead Pharmaceuticals make?

Arrowhead Pharmaceuticals has a market capitalization of $7.12 billion and generates $87.99 million in revenue each year. The biotechnology company earns $-84,550,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis.

How many employees does Arrowhead Pharmaceuticals have?

Arrowhead Pharmaceuticals employs 147,000 workers across the globe.

What is Arrowhead Pharmaceuticals' official website?

The official website for Arrowhead Pharmaceuticals is www.arrowheadpharma.com.

Where are Arrowhead Pharmaceuticals' headquarters?

Arrowhead Pharmaceuticals is headquartered at 177 E. Colorado Blvd Suite 700, Pasadena CA, 91105.

How can I contact Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals' mailing address is 177 E. Colorado Blvd Suite 700, Pasadena CA, 91105. The biotechnology company can be reached via phone at (626) 304-3400 or via email at [email protected]


This page was last updated on 7/24/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.